Key Publications

Transfusional Iron Overload

1. Adlette I et al, Absence of cardiac siderosis by MRI T2* despite transfusion burden, hepatic and serum iron overload in Lebanese patients with sickle cell disease. Eur Journal of Haematology 2009; "Accepted Article"; doi: 10.1111/j.1600-0609.2009.01345.x [Abstract]
   
2. Porter J, Concepts and goals in the management of iron overload. American Journal of Hematology 2007; 82: 1136-39.
3. Karam LB et al, Liver biospy results in patients with sickle cell disease on chronic transfusions: poor correlation with ferritin levels. Pediatric Blood and Cancer 2008; 50:62-65.
4. Olivieri NF and Brittenham G, Iron-chelating therapy and the treatment of thalassemia. Blood 1997; 89:739-61.
5. Min Y et al, A multi-center, open label study evaluating the efficacy of iron chelation therapy with deferasirox in transfusional iron overload patients with myelodysplastic syndromes or aplastic anemia using quantitative R2 MRI. Leukemia Research 2009; 33 (Supp1):S118-19
6. Greenberg P.L et al, Change in liver iron concentration (LIC), serum ferritin (SF) and labile plasma iron (LPI) over 1 year of deferasirox (Exjade^®) therapy in a cohort of patients with MDS. Leukemia Research 2009; 33 (Supp1):120

Hereditary Haemochromatosis

1. Olynyk JK et al, Predicting iron overload in hyperferritinemia. Clinical Gastroenterology and Hepatology 2009; 7:359-362. [abstract]
2. Olynyk JK et al, Duration of hepatic iron exposure increases the risk of significant fibrosis in hereditary hemochromatosis: a new role for magnetic resonance imaging. American Journal of Gastroenterology 2005; 100:837-841.
3. St Pierre TG el al, A new model for predicting venesection therapy requirement in hereditary hemochromatosis using non-invasive liver iron concentration measurement. Blood (ASH abstracts) 2005; 105: Abstract 3596.

Liver Iron Concentration

1. St Pierre TG, Using MRI to measure liver iron levels, TIF Magazine March 2009; 42-44
   
2. St Pierre TG et al, Noninvasive measurement and imaging of liver iron concentrations using proton magnetic resonance. Blood 2005; 105:855-61.
3. Angelucci E et al, Hepatic iron concentration and total body iron stores in thalassemia major. New England Journal of Medicine 2000; 343:327-31.
4. Telfer PT et al, Hepatic iron concentration combined with long-term monitoring of serum ferritin to predict complications of iron overload in thalassemia major. British Journal of Haematology 2000; 110:971-77.
5. Kowdley KV el al, Survival after liver transplantation in patients with hepatic iron overload: the national hemochromatosis transplant registry. Gastroenterology 2005; 129:494-503 [abstract]
6. Piga A et al, Comparison of LIC obtained from biopsy, BLS and R2-MRI in iron overload patients with ß-thalassemia, treated with deferasirox (Exjade^®, ICL670). Blood (ASH abstracts) 2005; 106: Abstract 2689.

Cardiac Iron Concentration

1. Patton N et al, Observational study of iron overload as assessed by magnetic resonance imaging (MRI) in an adult population of transfusion dependent patients with ß-thalassaemia: significant association between low cardiac T2* <10 ms and the occurence of cardiac events. Accepted Article; doi:10.1111/j.1445-5994.2009.01981.x [Abstract]
   
2. Jensen PD et al, Evaluation of myocardial iron by magnetic resonance imaging during iron chelation with deferrioxamine: indication of close relation between myocardial iron content and chelatable iron pool. Blood 2003; 101:4632-39.
3. Noetzli JL, Longitudinal analysis of heart and liver iron in thalassemia major. Blood 2008; 112:2973-78.
4. Anderson LJ et al, Cardiovascular T2-star (T2*) magnetic resonance for the early diagnosis of myocardial iron overload. European Heart Journal 2001; 22:2171-79.
5. Wood JC et al, Myocardial iron loading in transfusion-dependent thalassemia and sickle cell disease. Blood 2004; 1934-39.